Latest Distribution Agreements News

RLF AgTech has secured strategic distribution partnerships with two leading Indian agricultural groups, marking its commercial entry into one of the world’s largest crop nutrition markets. These agreements position RLF for rapid expansion in India’s vast and growing agricultural sector.

The Environmental Group Limited reported a robust first half of FY26 with revenue rising 8.6% to $58.9 million and underlying EBITDA jumping 25.9%, driven by strong performances in its Energy and Waste divisions alongside strategic operational upgrades.

EZZ Life Science Holdings has secured a four-year exclusive global distribution agreement with Aumake Limited, committing to at least A$10 million in purchases. This partnership aims to accelerate EZZ’s international reach while preserving brand control.

Aumake Limited has secured a four-year exclusive global distribution agreement with EZZ Life Sciences, targeting $10 million in sales and expanding its footprint in high-margin nutraceuticals.

Rhythm Biosciences has inked a non-exclusive distribution agreement with 4Cyte Pathology to integrate its ColoSTAT® colorectal cancer blood test into a vast pathology network across eastern Australia, aiming to boost adoption and accessibility.

BTC Health’s investee, BTC Cardio, has landed exclusive Australian distribution rights for Jafron Biomedical’s hemoperfusion cartridges, aiming for a 2026 market debut pending regulatory approval.

Osteopore Limited has secured an exclusive three-year distribution deal with Medprin Biotech GmbH to broaden its presence in Latin America's craniofacial reconstruction market, tapping into a region poised for significant growth.

AMP Limited reported a robust FY25 with underlying NPAT up 20.8%, driven by strong cashflow growth, cost reductions, and new product launches including AMP Bank GO and AMP Lifetime Pension. The company sets a steady course for FY26 with continued focus on retirement solutions and AI-driven innovation.

Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.

Terragen Holdings has raised A$7 million through a strategic equity raising to fund scientific research and accelerate global commercialisation, while appointing Dr Michele Allan AO as its new Chair.

First Graphene has secured a strategic distribution and collaboration agreement with Syron GreenThrust Dynamics to supply its PureGRAPH products across India, SAARC nations, and the UAE, unlocking new industrial markets and potential local manufacturing.

4DMedical has rapidly commercialised its CT – VQ™ lung imaging technology following FDA clearance, securing major partnerships and regulatory approvals that position it for significant growth in North America.